Advertisement: TTP
Advertisement EY mid banner
Advertisement: Cambridge Network
Barr Ellison Solicitors – commercial property
RealVNC mid-banner general
Advertisement: Simpsons Creative
RealVNC mid banner careers
Advertisement: Wild Knight Vodka
Advertisement: RSM
Mid banner advertisement: BDO
ARM Innovation Hub
Advertisement: EBCam mid banner
Advertisement: Mogrify
14 February, 2018 - 00:03 By Kate Sweeney

Domainex awarded £118k for novel drug research

Domainex, a Cambridge drug discovery services company, has been awarded £118,000 from the UK’s innovation agency, Innovate UK, to develop a new biophysical screening method for G-protein coupled receptors (GPCRs).

This investment represents a significant opportunity for the company to develop a technology to accelerate the discovery of new drugs.

“Domainex is developing a new way of starting GPCR drug discovery projects by using a biophysical technique called MicroScale Thermophoresis (MST), in combination with a method developed by Professor Tim Dafforn and his team at the University of Birmingham to stabilise the receptor,” explains Trevor Perrior, chief scientific officer at Domainex.

“This Biomedical Catalyst Feasibility Award from Innovate UK will enable Domainex scientists to test the feasibility of using this approach on GPCRs in order to establish a generic platform that would work for any purified GPCR without the need for stabilising mutations.”

Chief operating officer Tom Mander added: “This 12 month project will lead to a new service that Domainex can offer to prospective clients. It will facilitate our clients’ research projects meaning that better drugs will get to patients, faster.

“As an integrated drug discovery services provider, and the first CRO in the UK to offer fragment screening using MST, Domainex is in a unique position to innovate and advance drug discovery projects in this pivotal target class.”

• PHOTOGRAPH SHOWS: Trevor Perrior, CSO at Domainex

Newsletter Subscription

Stay informed of the latest news and features